- Home
- LBGJ vs KALA Comparison
LBGJ vs KALA Comparison
Compare LBGJ & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- KALA
- Stock Information
- Founded
- LBGJ 2007
- KALA 2009
- Country
- LBGJ China
- KALA United States
- Employees
- LBGJ N/A
- KALA N/A
- Industry
- LBGJ
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- LBGJ
- KALA Health Care
- Exchange
- LBGJ NYSE
- KALA Nasdaq
- Market Cap
- LBGJ 24.7M
- KALA 26.2M
- IPO Year
- LBGJ 2024
- KALA 2017
- Fundamental
- Price
- LBGJ $1.44
- KALA $8.40
- Analyst Decision
- LBGJ
- KALA Strong Buy
- Analyst Count
- LBGJ 0
- KALA 3
- Target Price
- LBGJ N/A
- KALA $14.00
- AVG Volume (30 Days)
- LBGJ 24.1K
- KALA 204.0K
- Earning Date
- LBGJ 08-15-2025
- KALA 08-05-2025
- Dividend Yield
- LBGJ N/A
- KALA N/A
- EPS Growth
- LBGJ N/A
- KALA N/A
- EPS
- LBGJ N/A
- KALA N/A
- Revenue
- LBGJ $11,781,015.00
- KALA N/A
- Revenue This Year
- LBGJ N/A
- KALA N/A
- Revenue Next Year
- LBGJ N/A
- KALA N/A
- P/E Ratio
- LBGJ N/A
- KALA N/A
- Revenue Growth
- LBGJ 21.82
- KALA N/A
- 52 Week Low
- LBGJ $1.02
- KALA $2.92
- 52 Week High
- LBGJ $5.50
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- KALA 74.24
- Support Level
- LBGJ N/A
- KALA $5.35
- Resistance Level
- LBGJ N/A
- KALA $8.49
- Average True Range (ATR)
- LBGJ 0.00
- KALA 0.79
- MACD
- LBGJ 0.00
- KALA 0.24
- Stochastic Oscillator
- LBGJ 0.00
- KALA 97.13
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.